ACTUATE THERAPEUTICS, INC. (ACTU)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 2,764,805 | |||
| General and administrative | 3,204,072 | |||
| Total operating expenses | 5,968,877 | |||
| Loss from operations | -5,968,877 | |||
| Interest income | 24,534 | |||
| Interest expense | 5,062 | |||
| Change in estimated fair value of warrant liability | - | |||
| Loss on issuance of related party convertible notes payable at fair value | - | |||
| Change in estimated fair value of related party convertible notes payable | - | |||
| Total other income (expense), net | 19,472 | |||
| Net loss | -5,949,405 | |||
| Net loss per share attributable to common stockholders, basic | -0.3 | |||
| Net loss per share attributable to common stockholders, diluted | -0.3 | |||
| Weighted-average shares of common stock outstanding, basic | 19,646,475 | |||
| Weighted-average shares of common stock outstanding, diluted | 19,646,475 | |||